Biomedical Research and Therapy Biomedical Research and Therapy http://www.bmrat.org/ Biomedical Research and Therapy 10.15419/bmrat.v9i12.782 Mesenchymal stem cell therapy for wound healing: An update to 2022 Huynh Phat Duc 1 Tran Quynh Xuan 2 Nguyen Sao Thi 2 Nguyen Vy Quang 2 0000-0003-4447-9212 Vu Ngoc Bich ngocvu@sci.edu.vn 2 Laboratory of Stem Cell Research and Application, University of Science Ho Chi Minh City, Viet Nam Vietnam National University Ho Chi Minh City, Viet Nam Stem Cell Institute, University of Science Ho Chi Minh City, Viet Nam International University, University of Science Ho Chi Minh City, Viet Nam 9 12 5437 5449 Abstract

The skin is an organ that performs complex functions of both the innate and adaptive immune systems. It serves as the first physical barrier to protect the body from environmental factors. Skin also carries aesthetic value in people’s desire for eternal youth. Skin lesions are often unwanted, causing open wounds that can be contagious or permit infection of the body, scars, skin aging, and loss of skin function, with long-term psychological consequences. The application of stem cell therapy based on mesenchymal stem cells (MSCs) is constantly developing in the field of skin regeneration, which is highly regarded as a therapy for patients suffering skin lesions from burns, deep wounds, cosmetic surgery, or genetic diseases. MSC therapy has shed light on groundbreaking treatments in immune, anti-inflammatory, and regenerative medicine, including for skin diseases. Additionally, the development of stem cells seems to limit skin aging. It is gradually becoming an integral technique at hospitals as a regular therapy for illness, as well as a cosmetic intervention. This review seeks to introduce the skin system and its related disorders; highlight the common characteristics and mechanisms of MSCs; and analyze updated clinical applications and experiments to date in MSC therapy for regenerative biomedicine and skin diseases.

Keywords MSC for skin scarring skin regeneration skin therapies Introduction

During the past decade, mesenchymal stem cells (MSCs) have emerged as a promising therapy for the treatment of many pathologies. Clinical trials of MSCs to treat chronic wounds that do not heal are underway. There is also interest in their therapeutic potential to accelerate the closure of burn wounds and treat autoimmune disease damage. Many studies show the positive effects of MSC therapy. These positive results are not due to MSCs’ differentiation to replace damaged skin. Their therapeutic effects derive from the secretion of soluble factors that regulate cellular responses to skin injury.

Despite the potential of MSC therapy, the field remains in its infancy, with many challenges to be addressed before it can be used effectively in clinical practice. Studies to determine the interactions between MSCs and different cell types in wounds are urgently needed. Such studies must also identify the MSC-derived factors that are responsible for regulating local cellular responses to injury and how the wound environment affects MSCs. This paper will review the current understanding of MSCs for wound healing.

 Skin and wound healing

Skin plays an exquisite, crucial role that involves different biological functions. It is the largest organ of the human body; in adults, it has an area of approximately 1.5 – 2 m2 and accounts for about 15% of body weight1, 2. The skin consists of different receptors to sense temperature, moisture, pain, and texture3. The skin regulates body temperature, stores water, and prevents dehydration to maintain the body’s internal balance and protect the body from negative conditions, such as extreme temperatures. The skin is also significant in metabolic processes, notably vitamin D synthesis and lipid storage2, 3. One of the most important functions of the skin system is to act as a protective barrier between the external and internal environment of the body2. Mechanically, the skin is constantly replenished to maintain a balance between cell death and regeneration. Sweat glands, sebaceous glands, and skin flora embedded within the skin layer also contribute greatly to the overall function of this organ4. The skin faces challenges due to aging (chronic) and wounds (acute).

Skin aging refers to the functional and aesthetic deterioration of the skin, diminishing its capacity to protect and regulate the body. Skin aging is characterized by the accumulation of damaged macromolecules in cells, diminution of regenerative capacity, and loss of physiological function5. Some discernible features of skin undergoing early again are thickening, deep wrinkles, spotting, and roughness6, 7.

Two types of skin aging occur simultaneously: aging over time and aging due to the effects of intrinsic factors (e.g., genetics, cell metabolism, hormones, etc.) and extrinsic factors (e.g., habitat, dust, radiation, toxins, chemicals, etc.). Over time, the accumulation of factors leads to molecular damage, including DNA mutation, telomere shortening, epigenetic alterations, etc., and cellular disorders, such as oxidative stress, cellular senescence, autophagy, proteostasis, inflammation, deficiency of the immune system, etc.8, 5. Thus, molecular changes due to genetic and epigenetic aging ultimately result in the aggregation of worn-out cells and the deterioration of tissue homeostasis and healing capacity9.

The extracellular components in the skin encompass collagen, elastin, fibrillin, and proteases. During aging, the ratio of type III collagen to type I collagen increases due to the loss of collagen I, which involves the down-regulation of the TGF-β/Smad signaling pathway and connective tissue growth factors; consequently, the architecture of the skin is poorly reconstructed10, 11. Moreover, the family of various matrix metalloproteinases (MMPs) exhibits a considerable impact on skin balance and anti-aging. MMPs originate from a common family of endopeptidases that decompose ECM proteins and, thus, promote the degradation of the skin12. This family has also been shown to increase with age, while endogenous MMP inhibitors decline correspondingly13, 14. Furthermore, reactive oxygen species (ROS) augment MMPs with age15. These elements could be synthesized internally as metabolized oxidizing precursors, or derive from external ultraviolet exposure. ROS activate the mitogen-activated protein kinase family (MAPK), which then induces MMP transcription factors16, 17. UV is associated with the NF-κB pathway, which is responsible for regulating MMP in skin fibroblasts16, 18.

Aging cells typically present a low expression of β-galactosidase, particularly those that are about to shift into senescence. Additionally, senescence-related gene expression, including CHEK1 and cyclin-dependent kinase inhibitor p16ink4a, is relatively down-regulated during aging9. Meticulous studies have revealed the dysregulation of microRNAs (miRNAs) as aging progresses. MiRNAs (short noncoding RNAs that bind to the 3’ untranslated region of target mRNA to prevent its gene expression) primarily serve as regulators for cell survival, proliferation, differentiation, and senescence19, 20. Age-dependent defectiveness restricts repair genes9.

The processes of skin regeneration and post-traumatic wound healing are indispensable, especially in the epidermal and dermal layers, as they help reduce the risk of infection that is associated with a high mortality rate21. This healing reaction occurs in three stages: the inflammatory phase, the proliferation phase, and the remodeling phase.

Skin injury triggers the inflammation response, which initiates coagulation, providing a fibrin network alongside vascular constriction to close the wound and preserve its integrity. This fibrin meshwork not only balances endogenous conditions and fights invading microorganisms, but also provides the site for cell migration and the collection of growth factors, including transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF)22. White blood cells are recruited into the site of injury within the first 24 hours and remain there for 2 to 5 days23, 24. White blood cells release protease and ROS to directly destroy bacteria, digest mortified tissue, and engulf the remnants of cell debris. Meanwhile, neutrophils appear to release cytokines, including necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, to amplify the inflammatory response25.

The proliferative phase occurs 48 after the wound occurs and can last for up to 14 days26 after the remission of inflammation, resulting in a miniature lesion when the contraction and formation of filaments induces horn cells26. This phase is characterized by granulation tissue formation to replace the provisional wound matrix and vascular network recovery of the sources of cytokines and growth factors, notably transforming growth factor-beta (TGF-beta, including TGF-β1, TGF-β2, and TGF-β3), interleukin (IL), and vascular formation factors27, 24. In response to tactile inhibition and the physical strain of endoplasmic lesions, horn cells and epithelial stem cells from hair follicles are triggered to migrate and proliferate to cover the wound margin. Furthermore, macrophages send nitric oxide28 signals or other cell types release epidermal growth factors (EGF), keratinocyte growth factors (KGF), insulin-like growth factor 1 (IGF-1), and neural growth factor (NGF), which appear to trigger the reepithelization process29, 30. Additionally, angiogenesis occurs to enable the transportation of nutrients and oxygen that favors wound healing. During the formation of new blood vessels, endothelial cells are activated by vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), and thrombin serine protease31. The final step of this process is marked by the formation of granulation tissue leading to the infiltration and proliferation of fibroblasts into the wound edge. Granulation tissue consists of loosely organized fibroblasts, macrophages, capillaries, granular leukocytes, and bundles of type III collagen3, 32.

The remodeling phase completes the healing process, beginning within 2 to 3 weeks of the injury and potentially lasting for a year33. The process of controlling the balance between the degeneration and synthesis of new tissue is immensely rigorous and any disruption or error results in the formation of chronic wounds24, 32. TGF-β1 promotes fibroblast differentiation into myofibroblasts34. The extracellular matrix (ECM) is remodeled and synthesized to become more robust, characterized by the degeneration of type III collagen over time and its gradual replacement with type I collagen32. However, some skin components, such as hair follicles or sweat glands, cannot recover from severe skin damage35. Thus, wound healing terminates with the formation of scars, which are closely related to inflammation34.

Mesenchymal stem cells and their bioeffects on skin regeneration Mesenchymal stem cells and their extracellular vesicles

MSCs have been found and isolated from various somatic locations36. Their biological functions have been assessed differently, as well as being isolated in different places with different methods; no distinct indication helped define the characterization of MSCs. To circumvent this problem, the International Society for Cellular Therapy suggested minimum standards to identify MSCs in humans37: First, MSCs must have a fibroblast shape, adhesive capacity, and maintain their shape under standard culture conditions. Second, MSCs must express CD73, CD90, and CD105 but not CD14, CD11b, or CD79α, CD19, CD34, CD45, and HLA-DR. Third, MSCs must differentiate into osteocytes, chondrocytes, and adipocytes in vitro37. Although scientists recently discovered that MSC populations do not thoroughly comply with these minimal criteria—for instance, some fail to express CD10538 —these rules are still ubiquitously used to compare and exchange data among MSC studies (Figure 1).

<bold id="s-77dc14bb8ccd">The minimal criteria in defining mesenchymal stem cells</bold>. (<bold id="s-f1c8e07202cc">1)</bold> MSCs must have a fibroblast shape, adhesive capacity, and shape maintenance in standard culture conditions. (<bold id="s-d19406cb19fe">2)</bold> MSCs must express positive expression for CD73, CD90, CD105, and negative expression for CD14 or CD11b or CD79α, CD19, CD34, CD45, and HLA-DR. (<bold id="s-70711be6c376">3)</bold> MSCs must differentiate into osteocytes, chondrocytes, and adipocytes <italic id="e-908a4ff16301">in vitro</italic>.

MSCs have been attested to work through the paracrine system via extracellular vesicles (EVs)39, 40. MSC-EVs comprise a variety of vesicles of varying sizes and are described as miniature prototypes of the cells that secrete them41. EVs can be divided into three main types by origin: apoptotic bodies (1000–5000 µm), microvesicles (1000 µm), and exosomes (30 – 150 µm)42. EVs seem to be more stable in the living body than foreign elements43. Immunoregulatory factors such as IL-10, TGF-β, INF- γ, IDO, and prostaglandin E2 persist within EVs44, 45. Their chief components include proteins, lipids, and nucleic acids. These components mediate many effects in recipient cells and are enclosed within a phospholipid bilayer. Furthermore, at least 730 different proteins have been shown to be enriched in exosomes derived from mesenchymal stem cells46. Additionally, 171 miRNAs have been pinpointed in EVs derived from MSCs47 and play pivotal roles in gene expression. For example, miR-130a-3p triggers cell proliferation, angiogenesis, the inhibition of programmed death, or the regulation of immune cell survival (https://www.ncbi.nlm.nih.gov/gene/406919). Exosomes have gradually revealed their potency and paved the way for the fourth generation of stem cell therapy.

<bold id="s-d86292ea8ea5">The cells of the innate and adaptive immune systems are affected under the regulation of MSCs</bold>. Arrows indicate activation or induction, T-bars indicate inhibition.

<bold id="strong-2">MSCs’ bioeffects on skin</bold> Immunomodulation

MSCs were first shown to regulate immunosuppressive activities in a mixture of lymphatic cells in vitro and persistent allograft in-vivo transplant rejection48. Since then, numerous studies have shown that MSCs mediate immunosuppression in both animal and human models. Their regulatory ability applies to both the innate and adaptive immune systems (Figure 2).

MSCs inhibit differentiation into type I macrophages49, 50, 51. IL-6 and insulin-like growth factor (IGF) prompt mononuclear cells to secrete IL-10, a strong anti-inflammatory cytokine that perpetuates osmotic balance, heals inflammatory tissue, and stimulates the transformation of macrophages into type 2 macrophages50. Additionally, MSC releases anti-ligands, such as interleukin 1 (IL1-RA) and PGE-2, which have similar effects52, 53.

MSC-derived IL-6 also inhibits apoptosis in neutrophils54. Neutrophils are the most common innate immune cells, appearing within hours in wounds. To date, the clinical associations between MSC and neutrophils are poorly understood. MSCs have been suggested to enhance neutrophil activity55, 56. MSCs also regulate a significant reduction in intracellular hydrogen peroxide, which affects neutrophils’ apoptosis process57. Neutrophils in environments with nutrient or serum deficiency can survive if cocultured with MSCs58.

Critically, MSC-secreted cytokines could inhibit pro-inflammatory T cells and stimulate the proliferation of regulatory T cells (Tregs)59, 60. Tregs are crucial for immune homeostasis because they prevent the autoimmune response. Growth factor B1 (TGFβ1), PGE2, and IL-10 innervate the increment of Tregs61, 62, 7. Although the mechanism of MSC immunomodulation remains largely unexplored, PGE2, IDO, HGF, and TGF-β1 have been strongly linked to the immunosuppression of T cells63. MSCs prohibit the production of IL-17, which suppresses the induction of Th1764, while the enhancement of IL-10 activates Tregs65. MSCs also secrete indoleamine 2,3-dioxygenase (IDO), an enzyme that decomposes tryptophan, which inhibits the growth of T cells by reducing tryptophan availability10. Several studies have suggested that a persistent decrease in tryptophan reduces the secretion of IL-4 in Th2 cells and the amount of Th1 released from IFN-gamma cells52, 66.

MSCs significantly enhance the immune regulation of B cells by mediating IL-1067, 68. One study demonstrated that the interaction of CD3+ T cells and MSCs inhibits the proliferation of plasma B cells69. At high IFN-γ concentrations, MSCs could activate programmed cell death receptors through direct contact and the PD-1/PD-L1 signaling pathway to hamper the growth and maturity of B cells70. Additionally, MSCs inhibit the CXCR4, CXCR5, and CCR7 molecules that directly affect B cells71.

MSCs inhibit the differentiation, maturity, and migration of DC cells72, 73. Specifically, IL-6 and IL-10 suppress the differentiation of mononuclear cells into DC cells74, 75. In addition, PGE2 is expected to demonstrate a similar inhibitory effect73. MSCs also promote the generation of regulatory DCs with immunomodulatory functions in mouse models76.

In addition, MSCs restrict NK cell proliferation, cytokine secretion, and cytotoxicity mediated by PGE2, IDO, HLA-5, or extracellular vesicles77, 12. This effect requires a higher ratio of MSCs to NK cells78. MSCs also regulate the CD73 expression of NK cells, which converts AMP to adenosine as an anti-inflammation inducer66, 79.

The effects that MSCs have on cells in the innate and adaptive immune systems are summarized in Table 1.

<bold id="s-f969b1c1c48b">The target cells affected by MSCs-derived cytokines<xref id="x-9b1599476f56" rid="R162101426652317" ref-type="bibr">80</xref></bold>

Target cell

MSCs-derived cytokines

Tregs

IL-6, IL-10, TGFβ, IDO, VEGF

NK

TGFβ, Chemokines, PGE2, IDO

B

IL-6, TGFβ, IDO

Th1

IL-10, CCL-5/RANTES, VEGF

Th2

IL-6, CCL-2/MCP-1

Th17

IL-6, CCL-2/MCP-1, VEGF

DCs

IL-10, IL-6, TGFβ, IDO, VEGF, PGE2

Neutrophils

IL-10, IL-6, CCL-5/RANTES

Monocytes

IL-6, CCL-5/RANTES, IDO, PGE2

MSC secretions in general and MSC-EVs, in particular, can modulate immunity and generate angiogenesis through their ability to regulate the proliferation and differentiation of cells. In the context of skin regeneration in general and chronic skin wounds, MSCs’ and MSC-EVs’ biological effects are apparent in infants: Early fetal skin wounds (< 3 months) heal and the skin regenerates without scarring81. The weak immune response found in fetal wounds reflects the low number of innate immune cells, such as neutrophils, macrophages, and mast cells, present82. This is characteristic of the difference between embryonic skin and adult skin.

The initial inflammatory process after the skin is wounded is very important, greatly affecting the skin composition, structure, and recovery through the subsequent processes. As Figure 2 shows, the products of MSCs exert regulatory effects on the cells of the innate and adaptive immune systems. They activate M2 macrophages and express signal transducers and activators of transcription 3 (STAT-3) concomitant with several transcription factors. These factors promote tissue regeneration and inhibit inflammation83, 84. In addition, MSCs increase the secretion of factors such as MCP-1, IL-6, and IL-8 to modulate inflammation85. Furthermore, MSCs inhibit T and B cell activation and the release of IL-10 and TGF-β—anti-inflammatory agents—and reduce IgE production86, 85.

 <bold id="strong-4">Regeneration</bold>

The evidence suggests that MSCs and their products work to maintain skin homeostasis. In adult bodies, subcutaneous ADSCs are responsible for regulating and directing mature differentiated cells outside the epidermis, especially keratinocytes. These cells are responsible for regeneration and recovery from damage87. MSCs also release several factors that help modulate the expression of various pathways6, 88. For example, several miRNAs in MSC-EVs activate the signaling pathways AKT, ERK, and STAT-3, which are involved in many cellular processes including angiogenesis, proliferation, and cell migration89.

Keratinocytes and fibroblasts play major roles in normal proliferation and healing. Fibroblasts primarily produce ECM, cause the oral contraction of the wound, biosynthesize collagen, and regenerate tissue. Disordered or over-synthesized collagen in fibroblasts will cause scarring. MSC-EVs have been shown to influence the MAPK/ER pathway of fibroblasts, reducing scarring during the treatment of open wounds90. In addition, MSCs promote wound healing through the PI3K/AKT signaling pathway91. Fibroblast proliferation is influenced by FGF, EGF, PDGF, TGF-β, CTGF, and IGF-192.

The re-epithelialization of the skin depends on the proliferation and migration of keratinocytes. These are among the most important processes in wound healing. The EGF and TGF-β of MSCs play an important role in keratinocyte migration93. In addition, keratinocyte proliferation is stimulated by bFGF, IGF-1, and EGF93.

 Mesenchymal stem cell transplantation: from animals to clinical trials

MSC therapy is promising as a fundamental therapy, with overwhelming advantages in regenerative capability, wound healing, and immunomodulation. Progressive effort has been made toward understanding the mechanisms by which MSCs promote skin wound healing. Studies of MSCs’ impact in animal models and their effect on skin lesions are presented in Table 2.

<bold id="s-47994018895b">Studies on MSCs’ effects on skin wounds in animal models</bold>

Number

Sources

Model

Result

References

1

Adipose-derived stem cells

Burned skin, Wistar rats

+

94

2

Adipose-derived stem cells

3rd-degree burns, BALB/c mice

+

95

3

Human amniotic mesenchymal stem cells

Burned skin, C57BL/6 mice

+

96

4

Human umbilical cord mesenchymal stem cells

Burned skin, C57BL/6 Mice

+

97

5

Adipose-derived stem cells

Surgical wound, Balb/c mice

+

36

6

Wharton’s jelly-derived mesenchymal stem cells

Radiation-induced skin wounds, rats

+

98

7

Human umbilical cord blood-derived mesenchymal stem cells

Imiquimod-induced psoriasis-like skin inflammation, C57/BL6 mice

+

99

8

Human umbilical cord-derived mesenchymal stem cells

Diabetic rats

+

100

9

Bone marrow mesenchymal stem cells

Wounds, Sprague-Dawley rats

+

101

10

Human umbilical cord Wharton’s jelly MSCs

Full-thickness skin defects, Balb/C mice

+

102

11

Umbilical cord and umbilical cord blood-derived mesenchymal stem cells

SKH-1 hairless mice

+

103

12

Human bone marrow and jaw bone marrow-derived mesenchymal stem cells

Full-thickness skin defects, C57BL/6J mice

+

104

<bold id="s-54953d1d7ef2">Clinical trials on the MSC and MSC products effects are registered (Clinicaltrial.gov), updated 2021</bold>

Number

Type

Phase

Nation

Ref

1

Corlicyte® umbilical cord lining mesenchymal stem cells

Phase 1

Usa

NCT04104451

2

Placental mesenchymal stem cells

Phase 1

China

NCT04464213

3

Umbilical Cord Lining Stem Cells

Phase 1

USA

NCT04723303

4

Adipose-derived mesenchymal stem cells

Phase 2

China

NCT04785027

5

Adipose-derived stromal/stem cells

Phase 2

France

NCT04356755

6

Umbilical Cord Mesenchymal Stem Cells

Early phase 1

China

NCT03765957

7

Mesenchymal stem cells -derived Exosome

Phase 2

USA

NCT04173650

8

Adipose-derived mesenchymal stem cells

Phase 2

Korea

NCT04137562

9

Umbilical Cord Mesenchymal Stem Cells

Pha 2

China

NCT03745417

10

Hematopoietic stem cells

Phase 3

Belgium, Croatia

NCT03754465

11

Adipose-derived mesenchymal stem cells

Phase 2

USA

NCT03754465

12

Human bone marrow-derived mesenchymal stem cells

Phase 2

Korea

NCT04179760

<bold id="s-21500b463844">Some products related to MSC and MSC-products in cosmetics on the current market</bold>

Number

Name

Sources

Nation

Ref

1

XoGlo®

Mesenchymal stem cell (MSC)-derived Exosome

USA

https://www.refineusa-exosomes.com/

2

HematoPAC™-HSC-CB

Umbilical cord blood stem cells

USA

https://www.businesswire.com/news/home/20210311005075

3

Venus Skin™

Bone Marrow Stem Cell

USA

https://www.venustreatments.com/en-us/sct-serum.htm

4

AnteAGE Serum

Bone Marrow Stem Cell

USA

https://anteage.com/products/anteage-pro-serum-30ml

5

Exo skin simple

Adipose Stromal Cell-derived Exosome

USA

https://exoskinsimple.com/collections/products

6

ASCE+ skin

Adipose Stromal Cell-derived Exosome

KOREA

http://www.asceplus.co.kr/

7

REBELLAXO

Umbilical cord blood- derived Exosome

USA

https://rebellabiologic.com/product/rebellaxo/

8

InfiniVive Exosome Serum

Umbilical cord blood-derived Exosome

USA

https://infinivivemd.com/products/infinivive-exosome-serum

9

CELL PERFORMANCE SERUM

Bone Marrow Stem Cell

KOREA

https://ndclist.com/ndc/60949-080

10

U AutologousTM

Stem cells derived from their

USA

https://www.leadingsalons.com/en/article/50/u-skincare

11

Dermaheal Stem C’rum

Adipose stem cell

KOREA

https://caregennordic.se/product/stem-crum/

12

Cutisera™

Bone marrow mesenchymal stem cell

INDIA

https://www.stempeutics.com/stempeucare.html

13

Adipose Stem Cell Growth Factor Anti-Aging Serum

Adipose Stem Cell

USA

https://www.amazon.com/Adipose-Hyaluronic-Matrixyl-Advanced-Anti-Aging/dp/B07SCPTSGN

14

Beautigenix Hydrating Mask

Adult Human Stem Cell

USA

https://incidecoder.com/products/beautygenix-hydrating-mask

15

ProPlus Eye Firming Complex

Peptides from Non-Embryonic Human Stem Cells

USA

https://lifelineskincare.com/products/proplus-eye-firming-complex

Most studies of MSCs’ relationship to skin wounds on different model types report positive effects. This dynamic supports the application of MSCs to human skin lesions. To date, more than 400 clinical studies affirm the positive effects of MSCs on skin lesions (clinicaltrials.gov). These studies use mesenchymal stem cells from a variety of sources; MSC products, such as EVs, proteins, or miRNAs; and these agents together, along with a biomatrix (tissue engineering) to treat skin wounds. Some of the most up-to-date clinical trials are presented in Table 3.

In addition to the use of MSCs to heal ailments related to skin damage, MSCs and MSC products have been used for anti-aging cosmetic purposes. Research on animal models showed that exosomes from young mice could transfer miR-126b-5p to the tissues of old mice and reverse the expression of aging-related molecules such as p16, mTOR, and IGF-1R. They also affect the expression of telomerase-related genes, including Mre11a, Tep1, Terf2, Men1, Tert, and Tnks, in old mice105. If this effect occurs in humans, MSCs in general and MSCs originating from umbilical cords or placentas, in particular, will be a potential source of cosmetic pharmaceuticals, eliminating other cosmetics that currently dominate the market.

The market for exosome-related cosmetics is flourishing. Some MSCs and MSC products used in cosmetics are presented in Table 4.

 Perspectives

Because MSCs and MSC exosomes manifest hypoimmunogenic properties, they are hopeful choices for treating chronic wounds, injuries, and plastic surgery incisions. This has huge potential in the field of tissue remodeling and engineering. Since the Physiology Nobel prize in 2013 was awarded to the three Laureates who presented insights into exosomes, studies of MSC exosomes have increased at a dizzying rate. According to Mordor Intelligence, the exosome market was reportedly worth 174.04 million USD in 2020 and is predicted to increase by 27.89% in this year (https://www.mordorintelligence.com/). The growing demand for anti-aging therapies drives much of the market. Furthermore, the availability of various methods for exosomal isolation and purification helps fuel further studies of exosome treatments.

Most research now focuses on proving the utility of MSC exosomes as a single treatment. Clinically, MSC exosomes should be used in combination with other therapies, such as laser, topical medication, surgery, etc. Consequently, more studies are needed to demonstrate the synergistic or inhibitory effects of MSC exosomes in combination with conventional treatments. Researchers are optimistic about the development of MSC therapy. Similarly, exosomes as a drug delivery system are a bright research path. For almost a decade, there has been tremendous progress in our understanding of all aspects of exosomes. Further improvements in drug-loading strategies and the optimization of these therapies are promising for future clinicians.

 The limitations of MSC-EV use

The extracellular secretions of MSCs, especially the exosomes, are being intensively studied for their notable features. MSCs’ impact via exosomes is significant in tissue repair. MSC therapy is gaining popularity and is known as fourth-generation stem cell therapy—the new cell-free therapy106. MSCs not only play an essential role in the treatment of wounds, skin regeneration, and anti-aging but also contribute to the treatment of immune-related diseases, tumors, and neurological disorders and are the standard by which to diagnose and prevent disease. In addition, exosomes from MSCs can be used for drug delivery, encasing pharmaceuticals in a phospholipid bilayer that confers outstanding physiological advantages107.

In contrast, the considerations for using MSC exosomes include:

It is challenging to determine the composition of exosomes, such as their proteins, lipids, and, especially, miRNAs. All of these components derive from the cell culture process and are variable and heterogeneous. Qualitative studies generally seek to confirm whether an agent of interest persists within exosomes. The half-life of exosomes is also unknown. This is an important evaluation criterion to use exosomes for drug transport107. Drug efficacy is highly dependent on delivery time, so this is a major limitation of knowledge regarding the potential use of exosomes for transport.

Another important consideration is the exosome productivity of mesenchymal stem cells. The exosomes for this new cell-free therapy are usually obtained from MSC cultures. This means that cell therapy and exosome therapy are linked. A study has determined that producing sufficient exosomes to have the same effect as cell therapy requires 10 – 25 times the normal quantity of MSCs108. Significant development is needed before exosome therapy can be routinely applied. More research on a suitable culture medium to produce more extracellular vesicles is needed to address this limitation. The current cell culture abandonment medium does not meet the conditions required to develop a routine therapy.

There is also substantial concern about cell properties. Exosomes reflect the properties of their parent cells. Research shows that exosomes from young cells can reverse the aging of aging cells105. Therefore, more in-depth studies are needed on the relationship between MSC age and the exosomes they release. This greatly affects the potential of mesenchymal stem cells from different sites. If the assertions in105 are true, mesenchymal stem cells obtained from umbilical cords and placentas will be preferred.

Another problem in the production of exosomes is purity. MSCs do not express HLA-DR, so they should not induce an adverse immune response. However, an immune response has been observed when MSCs enter the body. This is associated with impurities in the injections. Ultracentrifugation is a standard method for exosome isolation and purification. It uses a density gradient, which may permit other agents or types of vesicles with the same density as the target components to remain. Developing an environment to eliminate, limit, or replace undesirable elements is one solution. However, the optimization of the culture and acquisition process is the ideal way to eliminate this problem.

Despite these limitations, the enormous potential of MSC exosomes is apparent. Exosomes have many advantages over mesenchymal stem cell therapy: They can be stored as proteins for short-term use without the concern of cell survival and using them after thawing is much easier. They are much smaller than MSCs and do not become trapped in small capillaries like cells do. One report shows that this is a serious limitation of cell therapy, as when intravenous administration results in pulmonary embolism109. However, exosome therapy cannot completely replace mesenchymal stem cell therapy because of their interrelationships.

 Abbreviations

AMP: Adenosine monophosphate, bFGF: Basic fibroblast growth factor, CCL-2/ MCP1: Chemokine (C-C motif) ligand 2/ onocyte chemoattractant protein 1, CCL-5/ RANTES: Chemokine (C-C motif) ligand 5/ regulated on activation, normal T cell expressed and secreted, CXCR4 C-X-C: chemokine receptor type 4, CXCR5 C-X-C: chemokine receptor type 5, DCs: Dendritic cells, ECM: Extracellular matrix, EGF: Epidermal growth factor, EVs: Extracellular vesicles, HGF: Hepatocyte growth factor, HLA-5: Human Leukocyte Antigen - 5, HLA-DR: Human Leukocyte Antigen – DR isotype, IDO: Enzyme Indoleamine 2,3-dioxygenase, IGF-1: Insulin-like growth factor 1, IL: Interleukin, KGF: Keratinocyte Growth Factor, MAPK: Mitogen-activated protein kinase, MMP: Matrix metalloproteinase, MSC: Mesenchymal stem cell, NK cells: Natural killer cells, NGF: Nerve growth factor, PDGF: Platelet-derived growth factor, PGE-2: Prostaglandin E 2, ROS: Reactive oxygen species, TGF-β: Transforming growth factor beta, TGF-β1: Transforming growth factor beta 1, TGF-β2: Transforming growth factor beta 2, TGF-β3: Transforming growth factor beta 3, TNF: Tumor necrosis factor, Th1 cells: T helper cells, Th2 cells: T helper cells, Tregs: Regulatory T cells, VEGF: Vascular endothelial growth factor, IFN-γ: Interferons γ

 Acknowledgments

This research is funded by Vietnam National University Ho Chi Minh City (VNU-HCM) under grant number 562-2020-18-03.

Author’s contributions

Phat Duc Huynh was responsible for the layout and content of the manuscript. Quynh Xuan Tran, Vy Quang Nguyen, and Sao Thi Nguyen equally contributed to this work. Ngoc Bich Vu conceptualized, coordinated and edited the article.

 Funding

Vietnam National University Ho Chi Minh City (VNUHCM) under grant number 562-2020-18-03.

 Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References Richardson M. Understanding the structure and function of the skin Nursing Times 2003 99 31 46 8 0954-7762 13677123 Vig K. Chaudhari A. Tripathi S. Dixit S. Advances in Skin Regeneration Using Tissue Engineering Int J Mol Sci 2017 18 4 789 10.3390/ijms18040789 28387714 Agarwal S.K. Skin. [Updated 2020 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 2021 Sanford J.A. Gallo R.L. Functions of the skin microbiota in health and disease Seminars in Immunology 2013 25 5 370 7 1096-3618 10.1016/j.smim.2013.09.005 24268438 Orioli D. Dellambra E. Epigenetic Regulation of Skin Cells in Natural Aging and Premature Aging Diseases Cells 2018 7 12 268 10.3390/cells7120268 30545089 Ferreira A. D. F. Gomes D. A. Stem Cell Extracellular Vesicles in Skin Repair Bioengineering (Basel) 2018 6 1 4 10.3390/bioengineering6010004 30598033 Luz-Crawford P. Kurte M. Bravo-Alegría J. Contreras R. Nova-Lamperti E. Tejedor G. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells Stem Cell Research & Therapy 2013 4 3 65 1757-6512 10.1186/scrt216 23734780 Ferrucci L. Gonzalez-Freire M. Fabbri E. Simonsick E. Tanaka T. Moore Z. Measuring biological aging in humans: A quest Aging Cell 2020 19 2 e13080 1474-9726 10.1111/acel.13080 31833194 Alt E.U. Senst C. Murthy S.N. Slakey D.P. Dupin C.L. Chaffin A.E. Aging alters tissue resident mesenchymal stem cell properties Stem Cell Research (Amsterdam) 2012 8 2 215 25 1876-7753 10.1016/j.scr.2011.11.002 22265741 Perez-Sepulveda A. Torres M.J. Khoury M. Illanes S.E. Innate immune system and preeclampsia Frontiers in Immunology 2014 5 244 1664-3224 10.3389/fimmu.2014.00244 24904591 Quan T. Shao Y. He T. Voorhees J.J. Fisher G.J. Reduced expression of connective tissue growth factor (CTGF/CCN2) mediates collagen loss in chronologically aged human skin The Journal of Investigative Dermatology 2010 130 2 415 24 1523-1747 10.1038/jid.2009.224 19641518 Qu M. Cui J. Zhu J. Ma Y. Yuan X. Shi J. Bone marrow-derived mesenchymal stem cells suppress NK cell recruitment and activation in PolyI:C-induced liver injury Biochemical and Biophysical Research Communications 2015 466 2 173 9 1090-2104 10.1016/j.bbrc.2015.08.125 26342798 Qin Z. Balimunkwe R.M. Quan T. Age-related reduction of dermal fibroblast size upregulates multiple matrix metalloproteinases as observed in aged human skin in vivo British Journal of Dermatology 2017 177 5 1337 48 1365-2133 10.1111/bjd.15379 28196296 Quan T. Little E. Quan H. Qin Z. Voorhees J.J. Fisher G.J. Elevated matrix metalloproteinases and collagen fragmentation in photodamaged human skin: impact of altered extracellular matrix microenvironment on dermal fibroblast function The Journal of Investigative Dermatology 2013 133 5 1362 6 1523-1747 10.1038/jid.2012.509 23466932 Quan T. Fisher G.J. Role of Age-Associated Alterations of the Dermal Extracellular Matrix Microenvironment in Human Skin Aging: A Mini-Review Gerontology 2015 61 5 427 34 1423-0003 10.1159/000371708 25660807 Chiang H.M. Chen H.C. Chiu H.H. Chen C.W. Wang S.M. Wen K.C. Neonauclea reticulata (Havil.) Merr Stimulates Skin Regeneration after UVB Exposure via ROS Scavenging and Modulation of the MAPK/MMPs/Collagen Pathway Evidence-Based Complementary and Alternative Medicine 2013 2013 324864 1741-427X 10.1155/2013/324864 23843873 Kim J. Lee C.W. Kim E.K. Lee S.J. Park N.H. Kim H.S. Inhibition effect of Gynura procumbens extract on UV-B-induced matrix-metalloproteinase expression in human dermal fibroblasts Journal of Ethnopharmacology 2011 137 1 427 33 1872-7573 10.1016/j.jep.2011.04.072 21672616 Pittayapruek P. Meephansan J. Prapapan O. Komine M. Role of Matrix Metalloproteinases in Photoaging and Photocarcinogenesis Int J Mol Sci 2016 17 6 868 10.3390/ijms17060868 27271600 Ambros V. The functions of animal microRNAs Nature 2004 431 7006 350 5 1476-4687 10.1038/nature02871 15372042 Bartel D.P. MicroRNAs: target recognition and regulatory functions Cell 2009 136 2 215 33 1097-4172 10.1016/j.cell.2009.01.002 19167326 Jeschke M.G. Rehou S. McCann M.R. Shahrokhi S. Allogeneic mesenchymal stem cells for treatment of severe burn injury Stem Cell Research & Therapy 2019 10 1 337 1757-6512 10.1186/s13287-019-1465-9 31752987 Vahabi S. Vaziri S. Torshabi M. Rezaei Esfahrood Z. Effects of Plasma Rich in Growth Factors and Platelet-Rich Fibrin on Proliferation and Viability of Human Gingival Fibroblasts Journal of Dentistry (Tehran) 2015 12 7 504 12 1735-2150 26877740 Gantwerker E.A. Hom D.B. Skin: histology and physiology of wound healing Facial Plastic Surgery Clinics of North America 2011 19 3 441 53 1558-1926 10.1016/j.fsc.2011.06.009 21856533 Wang P.H. Huang B.S. Horng H.C. Yeh C.C. Chen Y.J. Wound healing Journal of the Chinese Medical Association 2018 81 2 94 101 1728-7731 10.1016/j.jcma.2017.11.002 29169897 Eming S.A. Martin P. Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation Science Translational Medicine 2014 6 265 1946-6242 10.1126/scitranslmed.3009337 25473038 Li J. Chen J. Kirsner R. Pathophysiology of acute wound healing Clinics in Dermatology 2007 25 1 9 18 0738-081X 10.1016/j.clindermatol.2006.09.007 17276196 Sorg H. Tilkorn D.J. Hager S. Hauser J. Mirastschijski U. Skin Wound Healing: An Update on the Current Knowledge and Concepts European Surgical Research 2017 58 1-2 81 94 1421-9921 10.1159/000454919 27974711 Witte M.B. Barbul A. Role of nitric oxide in wound repair American Journal of Surgery 2002 183 4 406 12 0002-9610 10.1016/S0002-9610(02)00815-2 11975928 Barrientos S. Stojadinovic O. Golinko M.S. Brem H. Tomic-Canic M. Growth factors and cytokines in wound healing Wound Repair and Regeneration 2008 16 5 585 601 1524-475X 10.1111/j.1524-475X.2008.00410.x 19128254 Landén N.X. Li D. St\aahle M. Transition from inflammation to proliferation: a critical step during wound healing Cellular and Molecular Life Sciences 2016 73 20 3861 85 1420-9071 10.1007/s00018-016-2268-0 27180275 Li J. Zhang Y.P. Kirsner R.S. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix Microscopy Research and Technique 2003 60 1 107 14 1059-910X 10.1002/jemt.10249 12500267 Kangal M.K. Ozgok Wound Healing. [Updated 2020 Jul 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535406/ 2021 Reinke J.M. Sorg H. Wound repair and regeneration European Surgical Research 2012 49 1 35 43 1421-9921 10.1159/000339613 22797712 Broughton G. Janis J.E. Attinger C.E. The basic science of wound healing Plastic and Reconstructive Surgery 2006 117 7 12 34 1529-4242 10.1097/01.prs.0000225430.42531.c2 16799372 Schilling J.A. Wound healing The Surgical Clinics of North America 1976 56 4 859 74 0039-6109 10.1016/S0039-6109(16)40983-7 959948 Luo Y. Yi X. Liang T. Jiang S. An Update on the Potential of Mesenchymal Stem Cell Therapy for Cutaneous Diseases Stem Cells Int 2019 2021 8834590 10.1186/s13287-019-1389-4 33505474 Dominici M. Le Blanc K. Mueller I. Slaper-Cortenbach I. Marini F. Krause D. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy 2006 8 4 315 7 1465-3249 10.1080/14653240600855905 16923606 The subpopulation of CD105 negative mesenchymal stem cells show strong immunomodulation capacity compared to CD105 positive mesenchymal stem cells Biomedical Research and Therapy 2019 6 4 3131 40 10.15419/bmrat.v6i4.538 Ranganath S.H. Levy O. Inamdar M.S. Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease Cell Stem Cell 2012 10 3 244 58 1875-9777 10.1016/j.stem.2012.02.005 22385653 Sajeesh S. Broekelman T. Mecham R.P. Ramamurthi A. Stem cell derived extracellular vesicles for vascular elastic matrix regenerative repair Acta Biomaterialia 2020 113 267 78 1878-7568 10.1016/j.actbio.2020.07.002 32645438 Worthington E. N. Hagood J. S. Therapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease Int J Mol Sci 2020 21 7 2318 10.3390/ijms21072318 32230828 Jeppesen D.K. Fenix A.M. Franklin J.L. Higginbotham J.N. Zhang Q. Zimmerman L.J. Reassessment of Exosome Composition Cell 2019 177 2 1097-4172 10.1016/j.cell.2019.02.029 30951670 Pluchino S. Smith J.A. Explicating Exosomes: Reclassifying the Rising Stars of Intercellular Communication Cell 2019 177 2 225 7 1097-4172 10.1016/j.cell.2019.03.020 30951665 Crain S.K. Robinson S.R. Thane K.E. Davis A.M. Meola D.M. Barton B.A. Extracellular Vesicles from Wharton's Jelly Mesenchymal Stem Cells Suppress CD4 Expressing T Cells Through Transforming Growth Factor Beta and Adenosine Signaling in a Canine Model Stem Cells and Development 2019 28 3 212 26 1557-8534 10.1089/scd.2018.0097 30412034 Lopatina T. Bruno S. Tetta C. Kalinina N. Porta M. Camussi G. Platelet-derived growth factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential Cell Communication and Signaling 2014 12 1 26 1478-811X 10.1186/1478-811X-12-26 24725987 Kim H.S. Choi D.Y. Yun S.J. Choi S.M. Kang J.W. Jung J.W. Proteomic analysis of microvesicles derived from human mesenchymal stem cells Journal of Proteome Research 2012 11 2 839 49 1535-3907 10.1021/pr200682z 22148876 Ferguson S. W. Wang J. Lee C. J. Liu M. The microRNA regulatory landscape of MSC-derived exosomes: a systems view Sci Rep 2018 8 1 1419 10.1038/s41598-018-19581-x 29362496 Bartholomew A. Sturgeon C. Siatskas M. Ferrer K. McIntosh K. Patil S. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo Experimental Hematology 2002 30 1 42 8 0301-472X 10.1016/S0301-472X(01)00769-X 11823036 Deng Y. Zhang Y. Ye L. Zhang T. Cheng J. Chen G. Umbilical Cord-derived Mesenchymal Stem Cells Instruct Monocytes Towards an IL10-producing Phenotype by Secreting IL6 and HGF Scientific Reports 2016 6 1 37566 2045-2322 10.1038/srep37566 27917866 Weiss A.R. Dahlke M.H. Immunomodulation by Mesenchymal Stem Cells (MSCs): Mechanisms of Action of Living, Apoptotic, and Dead MSCs Frontiers in Immunology 2019 10 1191 1664-3224 10.3389/fimmu.2019.01191 31214172 Zheng G. Huang R. Qiu G. Ge M. Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis Cell Tissue Res 2018 374 1 1 15 10.1007/s00441-018-2871-5 29955951 Abumaree M.H. Al Jumah M.A. Kalionis B. Jawdat D. Al Khaldi A. Abomaray F.M. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages Stem Cell Reviews and Reports 2013 9 5 620 41 2629-3277 10.1007/s12015-013-9455-2 23812784 Luz-Crawford P. Djouad F. Toupet K. Bony C. Franquesa M. Hoogduijn M.J. Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation Stem Cells (Dayton, Ohio) 2016 34 2 483 92 1549-4918 10.1002/stem.2254 26661518 Raffaghello L. Bianchi G. Bertolotto M. Montecucco F. Busca A. Dallegri F. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche Stem Cells (Dayton, Ohio) 2008 26 1 151 62 1549-4918 10.1634/stemcells.2007-0416 17932421 Hall S.R. Tsoyi K. Ith B. Padera R.F. Lederer J.A. Wang Z. Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils Stem Cells (Dayton, Ohio) 2013 31 2 397 407 1549-4918 10.1002/stem.1270 23132816 Le Blanc K. Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system Nature Reviews. Immunology 2012 12 5 383 96 1474-1741 10.1038/nri3209 22531326 Dallegri F. Ottonello L. Tissue injury in neutrophilic inflammation Inflammation Research 1997 46 10 382 91 1023-3830 10.1007/s000110050208 9372309 Maqbool M. Vidyadaran S. George E. Ramasamy R. Human mesenchymal stem cells protect neutrophils from serum-deprived cell death Cell Biology International 2011 35 12 1247 51 1095-8355 10.1042/CBI20110070 21649586 Baharlou R. Rashidi N. Ahmadi-Vasmehjani A. Khoubyari M. Sheikh M. Erfanian S. Immunomodulatory Effects of Human Adipose Tissue-derived Mesenchymal Stem Cells on T Cell Subsets in Patients with Rheumatoid Arthritis Iranian Journal of Allergy, Asthma, and Immunology 2019 18 1 114 9 1735-1502 10.18502/ijaai.v18i1.637 30848580 Jimenez-Puerta G. J. Marchal J. A. E. López-Ruiz P. Gálvez-Martín Role of Mesenchymal Stromal Cells as Therapeutic Agents: Potential Mechanisms of Action and Implications in Their Clinical Use J Clin Med 2020 9 2 445 10.3390/jcm9020445 32041213 English K. Ryan J.M. Tobin L. Murphy M.J. Barry F.P. Mahon B.P. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells Clinical and Experimental Immunology 2009 156 1 149 60 1365-2249 10.1111/j.1365-2249.2009.03874.x 19210524 Gonzalez-Rey E. Gonzalez M.A. Varela N. O'Valle F. Hernandez-Cortes P. Rico L. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis Annals of the Rheumatic Diseases 2010 69 1 241 8 1468-2060 10.1136/ard.2008.101881 19124525 Xu C. Yu P. Han X. Du L. Gan J. Wang Y. TGF-β promotes immune responses in the presence of mesenchymal stem cells Journal of Immunology (Baltimore, Md.: 1950) 2014 192 1 103 9 1550-6606 10.4049/jimmunol.1302164 24293629 Han X. Yang Q. Lin L. Xu C. Zheng C. Chen X. Interleukin-17 enhances immunosuppression by mesenchymal stem cells Cell Death and Differentiation 2014 21 11 1758 68 1476-5403 10.1038/cdd.2014.85 25034782 Liu H. Li R. Liu T. Yang L. Yin G. Xie Q. Immunomodulatory Effects of Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Rheumatoid Arthritis Frontiers in Immunology 2020 11 1912 1664-3224 10.3389/fimmu.2020.01912 32973792 Chatterjee D. Tufa D.M. Baehre H. Hass R. Schmidt R.E. Jacobs R. Natural killer cells acquire CD73 expression upon exposure to mesenchymal stem cells Blood 2014 123 4 594 5 1528-0020 10.1182/blood-2013-09-524827 24458278 Carreras-Planella L. Monguió-Tortajada M. Borràs F.E. Franquesa M. Corrigendum: Immunomodulatory Effect of MSC on B Cells Is Independent of Secreted Extracellular Vesicles Frontiers in Immunology 2019 10 2413 1664-3224 10.3389/fimmu.2019.02413 31660058 Chen X. Cai C. Xu D. Liu Q. Zheng S. Liu L. Human Mesenchymal Stem Cell-Treated Regulatory CD23+CD43+ B Cells Alleviate Intestinal Inflammation Theranostics 2019 9 16 4633 47 1838-7640 10.7150/thno.32260 31367246 Rosado M.M. Bernardo M.E. Scarsella M. Conforti A. Giorda E. Biagini S. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells Stem Cells and Development 2015 24 1 93 103 1557-8534 10.1089/scd.2014.0155 25036865 Schena F. Gambini C. Gregorio A. Mosconi M. Reverberi D. Gattorno M. Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus Arthritis and Rheumatism 2010 62 9 2776 86 1529-0131 10.1002/art.27560 20496367 Corcione A. Benvenuto F. Ferretti E. Giunti D. Cappiello V. Cazzanti F. Human mesenchymal stem cells modulate B-cell functions Blood 2006 107 1 367 72 0006-4971 10.1182/blood-2005-07-2657 16141348 Ge W. Jiang J. Arp J. Liu W. Garcia B. Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression Transplantation 2010 90 12 1312 20 1534-6080 10.1097/TP.0b013e3181fed001 21042238 Melief S.M. Geutskens S.B. Fibbe W.E. Roelofs H. Multipotent stromal cells skew monocytes towards an anti-inflammatory function: the link with key immunoregulatory molecules Haematologica 2013 98 9 e121 2 1592-8721 10.3324/haematol.2013.093864 24006414 Allavena P. Piemonti L. Longoni D. Bernasconi S. Stoppacciaro A. Ruco L. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages European Journal of Immunology 1998 28 1 359 69 0014-2980 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4 9485215 Djouad F. Charbonnier L.M. Bouffi C. Louis-Plence P. Bony C. Apparailly F. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism Stem Cells (Dayton, Ohio) 2007 25 8 2025 32 1066-5099 10.1634/stemcells.2006-0548 17510220 Krasnodembskaya A. Samarani G. Song Y. Zhuo H. Su X. Lee J.W. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes American Journal of Physiology. Lung Cellular and Molecular Physiology 2012 302 10 1003 13 1522-1504 10.1152/ajplung.00180.2011 22427530 Jeyaraman M. John A. Koshy S. Ranjan R. Anudeep T.C. Jain R. Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19 Biochimica et Biophysica Acta. Molecular Basis of Disease 2021 1867 2 166014 1879-260X 10.1016/j.bbadis.2020.166014 33232817 Sotiropoulou P.A. Perez S.A. Gritzapis A.D. Baxevanis C.N. Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells Stem Cells (Dayton, Ohio) 2006 24 1 74 85 1066-5099 10.1634/stemcells.2004-0359 16099998 Chen X. Shao H. Zhi Y. Xiao Q. Su C. Dong L. CD73 Pathway Contributes to the Immunosuppressive Ability of Mesenchymal Stem Cells in Intraocular Autoimmune Responses Stem Cells and Development 2016 25 4 337 46 1557-8534 10.1089/scd.2015.0227 26650818 Kyurkchiev D. Bochev I. Ivanova-Todorova E. Mourdjeva M. Oreshkova T. Belemezova K. Secretion of immunoregulatory cytokines by mesenchymal stem cells World Journal of Stem Cells 2014 6 5 552 70 1948-0210 10.4252/wjsc.v6.i5.552 25426252 Lorenz H.P. Whitby D.J. Longaker M.T. Adzick N.S. Fetal wound healing. The ontogeny of scar formation in the non-human primate Annals of Surgery 1993 217 4 391 6 0003-4932 10.1097/00000658-199304000-00011 8466310 Eming S. A. Wynn T. A. Inflammation and metabolism in tissue repair and regeneration Science 2017 356 6342 1026 1030 10.1126/science.aam7928 28596335 Jin L. Deng Z. Zhang J. Yang C. Liu J. Han W. Mesenchymal stem cells promote type 2 macrophage polarization to ameliorate the myocardial injury caused by diabetic cardiomyopathy Journal of Translational Medicine 2019 17 1 251 1479-5876 10.1186/s12967-019-1999-8 31382970 Liu Y.C. Zou X.B. Chai Y.F. Yao Y.M. Macrophage polarization in inflammatory diseases International Journal of Biological Sciences 2014 10 5 520 9 1449-2288 10.7150/ijbs.8879 24910531 Mazini L. Rochette L. Hamdan Y. Malka G. Skin Immunomodulation during Regeneration: Emerging New Targets J Pers Med 2021 11 2 85 10.3390/jpm11020085 33573342 Daltro S.R. Meira C.S. Santos I.P. Ribeiro Dos Santos R. Soares M.B. Mesenchymal Stem Cells and Atopic Dermatitis: A Review Frontiers in Cell and Developmental Biology 2020 8 326 2296-634X 10.3389/fcell.2020.00326 32478072 Blanpain C. Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin Nature Reviews. Molecular Cell Biology 2009 10 3 207 17 1471-0080 10.1038/nrm2636 19209183 Choi E. W. Seo M. K. Woo E. Y. Kim S. H. Exosomes from human adipose-derived stem cells promote proliferation and migration of skin fibroblasts Exp Dermatol 2018 27 10 1170 1172 10.1111/exd.13451 28940813 Ding J. Wang X. Chen B. Zhang J. Exosomes Derived from Human Bone Marrow Mesenchymal Stem Cells Stimulated by Deferoxamine Accelerate Cutaneous Wound Healing by Promoting Angiogenesis Biomed Res Int 2019 2019 9742765 31192260 Wang L. Hu L. Zhou X. Xiong Z. Zhang C. Shehada H.M. Exosomes secreted by human adipose mesenchymal stem cells promote scarless cutaneous repair by regulating extracellular matrix remodelling Scientific Reports 2017 7 1 13321 2045-2322 10.1038/s41598-017-12919-x 29042658 Zhang W. Bai X. Zhao B. Li Y. Zhang Y. Li Z. Cell-free therapy based on adipose tissue stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway Experimental Cell Research 2018 370 2 333 42 1090-2422 10.1016/j.yexcr.2018.06.035 29964051 Lee S.H. Jin S.Y. Song J.S. Seo K.K. Cho K.H. Paracrine effects of adipose-derived stem cells on keratinocytes and dermal fibroblasts Annals of Dermatology 2012 24 2 136 43 2005-3894 10.5021/ad.2012.24.2.136 22577262 Bhora F.Y. Dunkin B.J. Batzri S. Aly H.M. Bass B.L. Sidawy A.N. Effect of growth factors on cell proliferation and epithelialization in human skin The Journal of Surgical Research 1995 59 2 236 44 0022-4804 10.1006/jsre.1995.1160 7543631 Li J.-Y. Ren K.-K. Zhang W.-J. Xiao L. Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cell apoptosis and enhancing their proliferation through activating PI3K/AKT signaling pathway Stem Cell Res Ther 2019 10 1 247 10.1186/s13287-019-1366-y 31399039 Zhou P. Li X. Zhang B. Shi Q. A human umbilical cord mesenchymal stem cell-conditioned medium/chitosan/collagen/β-glycerophosphate thermosensitive hydrogel promotes burn injury healing in mice Biomed Res Int 2019 2019 5768285 10.1155/2019/5768285 31886229 Sun J. Zhang Y. Song X. Zhu J. The Healing Effects of Conditioned Medium Derived from Mesenchymal Stem Cells on Radiation-Induced Skin Wounds in Rats Cell Transplant 2019 28 1 105 115 10.1177/0963689718807410 30350716 Lee Y. S. Sah S. K. Lee J. H. Seo K.-W. Human umbilical cord blood-derived mesenchymal stem cells ameliorate psoriasis-like skin inflammation in mice Biochem Biophys Rep 2017 2016 281 288 10.1016/j.bbrep.2016.10.002 28956015 Wang L. Wang F. Zhao L. Yang W. Mesenchymal stem cells coated by the extracellular matrix promote wound healing in diabetic rats Stem Cells Int 2019 2019 9564869 10.1155/2019/9564869 30833970 Zheng X. Ding Z. Cheng W. Lu Q. Microskin‐Inspired Injectable MSC‐Laden Hydrogels for Scarless Wound Healing with Hair Follicles Advanced healthcare materials 2020 9 10 2000041 Zhao G. Liu F. Liu Z. Zuo K. MSC-derived exosomes attenuate cell death through suppressing AIF nucleus translocation and enhance cutaneous wound healing Stem cell research & therapy 2020 11 1 1 8 10.1186/s13287-020-01616-8 Myung H. Jang H. Myung J. K. Lee C. Platelet‐rich plasma improves the therapeutic efficacy of mesenchymal stem cells by enhancing their secretion of angiogenic factors in a combined radiation and wound injury model Experimental Dermatology 2020 29 2 158 67 10.1111/exd.14042 He X. Dong Z. Cao Y. Wang H. MSC-derived exosome promotes M2 polarization and enhances cutaneous wound healing Stem Cells Int 2019 2019 7132708 10.1155/2019/7132708 31582986 Chang Y.-W. Wu Y.-C. Huang S.-H. Wang H.-M. D. Autologous and not allogeneic adipose-derived stem cells improve acute burn wound healing PLoS One 2018 13 5 e0197744 10.1371/journal.pone.0197744 29787581 Gholipourmalekabadi M. Seifalian A. M. Urbanska A. M. Omrani M. D. 3D protein-based bilayer artificial skin for the guided scarless healing of third-degree burn wounds in vivo Biomacromolecules 2018 19 7 2409 2422 10.1021/acs.biomac.7b01807 29529861 Lee B.R. Kim J.H. Choi E.S. Cho J.H. Kim E. Effect of young exosomes injected in aged mice International Journal of Nanomedicine 2018 13 5335 45 1178-2013 10.2147/IJN.S170680 30254438 Pham P.V. Stem Cell Drugs-A New Generation of Biopharmaceuticals. Springer International Publishing; 2018 Oct 25. 2018 10.1007/978-3-319-99328-7 Wei W. Ao Q. Wang X. Cao Y. Liu Y. Zheng S.G. Mesenchymal Stem Cell-Derived Exosomes: A Promising Biological Tool in Nanomedicine Frontiers in Pharmacology 2021 11 590470 1663-9812 10.3389/fphar.2020.590470 33716723 Ahangar P. Mills S. J. Smith L. E. Strudwick X. L. Human multipotent adult progenitor cell-conditioned medium improves wound healing through modulating inflammation and angiogenesis in mice Stem Cell Res Ther 2020 11 1 299 10.1186/s13287-020-01819-z 32680566 Jung J.W. Kwon M. Choi J.C. Shin J.W. Park I.W. Choi B.W. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy Yonsei Medical Journal 2013 54 5 1293 6 1976-2437 10.3349/ymj.2013.54.5.1293 23918585